Reducing Your Risk

Hereditary Breast and Ovarian Cancer (HBOC)

If BRACAnalysis® testing confirms the presence of a BRCA1 or BRCA2 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer or detect cancer at an earlier, more treatable stage:

  • Increased surveillance for breast cancer in mutation carriers
  • Increased surveillance for ovarian cancer in mutation carriers
  • Risk-reducing medications for mutation carriers
  • Prophylactic surgery in mutation carriers

graph_01

Lynch Syndrome

If COLARIS® testing confirms the presence of a MLH1, MSH2, MSH6, PMS2 or EPCAM mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer or detect cancer at an earlier, more treatable stage:

  • Increased surveillance for colon, endometrial and ovarian cancer in mutation carriers
  • Surgical management for mutation carriers
  • Chemoprevention for mutation carriers
graph_02

Polyposis Syndromes

If COLARIS AP® testing confirms the presence of a APC or MYH mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer or detect cancer at an earlier, more treatable stage:

  • Increased surveillance and other interventions specifically for individuals with the APC orMYH gene mutations€” maximizing patient care and increasing clinical efficiency
  • Improved patient compliance with tailored screening recommendations and preventive measures
  • Significantly improved outcomes and reduced medical costs through early diagnosis and treatment of cancer, should it develop
  • Counseling for mutation carriers and their family members on the underlying cause of the cancer or adenomas

 

Hereditary Melanoma

If MELARIS® testing confirms the presence of a p16 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer or detect cancer at an earlier, more treatable stage.

  • Targeted screening and surveillance specifically for individuals with a p16 gene mutation €” maximizing patient care and increasing clinical efficiency
  • Improved patient compliance with tailored screening recommendations and preventive measures
  • Improved outcomes through prevention, earlier diagnosis and treatment of cancer, should it develop
  • Counseling for mutation carriers and their family members on the underlying cause of the pattern of melanoma and possibly pancreatic cancer

Hereditary Pancreatic Cancer

If PANEXIATM testing confirms the presence of a BRCA2 or PALB2 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer or detect cancer at an earlier, more treatable stage.

  • Targeted screening and surveillance specifically to individuals with a BRCA2 or PALB2 gene mutation €” maximizing patient care and increasing clinical efficiency
  • Improved patient compliance with tailored screening recommendations and preventive measures
  • Improved outcomes through prevention, earlier diagnosis and treatment of specific cancers, should they develop
  • Counseling for mutation carriers and their family members on the underlying cause of the cancer

 

To begin the process of seeing if genetic testing is right for you, check out Myriad’s Hereditary Cancer Quiz.

*Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare provider.